Monitor for advisory committee outcome in late July and PDUFA decision on August 2, 2026. A positive FDA decision would be transformative; negative outcome could pressure the stock.
REPL drugs
REPL drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 29 $11.20entry
- T+1 · 5mo ago −1.16%α −1.94% · $11.07
- T+5 · 4mo ago +2.41%α +1.02% · $11.47
- T+20 · 4mo ago −13.39%α −13.11% · $9.70
- T+60 · 8w ago +20.27%α +15.88% · $13.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Replimune reported a fiscal Q4 2026 EPS miss of -$0.77 vs -$0.72 consensus, a -6.9% surprise, with no revenue. The highlight is FDA acceptance of the RP1 BLA resubmission with a PDUFA date of August 2, 2026, and an advisory committee expected in late July, representing a pivotal near-term catalyst.
Key Financial Metrics
Key Facts
- FDA accepted RP1 BLA resubmission for advanced melanoma; PDUFA date August 2, 2026
- Advisory committee meeting expected in late July 2026
- Fiscal Q4 2026 EPS -$0.77 vs consensus -$0.72 (miss of $0.05)
- Cash and equivalents $268.9M as of March 31, 2026; cash runway into Q1 2027
- Net loss for Q4 $73.7M, full year $313.9M
Financial Impact
BLA approval could unlock significant revenue potential; no current product revenue. Cash burn rate suggests need for future financing if approval delayed.
Risk Factors
- FDA non-approval or complete response letter for RP1
- Cash burn may require dilutive financing before profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3318910 |
Track record
32 reports on REPL
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers